Efficacy

Brukinsa (Zanubrutinib) for Lymphoma

Brukinsa (zanubrutinib) is a Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in treating various types of lymphoma. Zanubrutinib has been designed to bind more selectively to the BTK enzyme, potentially offering a more targeted approach to treatment and reducing off-target effects. In clinical trials, Brukinsa has demonstrated promising results in patients with mantle cell lymphoma (MCL), a type of non-Hodgkin lymphoma. The drug has been granted accelerated approval by the FDA for the treatment of adult patients with MCL who have received at least one prior therapy. The efficacy of Brukinsa in MCL was evaluated in several clinical trials, where it showed high response rates and durable responses among patients.

In addition to MCL, Brukinsa is being investigated for its efficacy in treating other B-cell malignancies, including Waldenström's macroglobulinemia and marginal zone lymphoma. The outcomes from ongoing studies continue to support the potential role of zanubrutinib in providing a therapeutic benefit for patients with these conditions. As a BTK inhibitor, Brukinsa is part of a class of medications that have significantly impacted the treatment landscape for various B-cell lymphomas by offering an oral, targeted therapy option with a manageable safety profile.

Epkinly (Epcoritamab-bysp) for Lymphoma

Epkinly (epcoritamab-bysp) is an investigational bispecific antibody designed to target CD20, a protein expressed on the surface of B-cells, and CD3, a protein on T-cells. By engaging both B and T cells, epcoritamab aims to direct the body's immune system to attack and eliminate B-cell lymphoma cells. While still under clinical investigation, early phase trial results have shown that epcoritamab may have a role in the treatment of relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

The efficacy of Epkinly in clinical trials has been evaluated based on overall response rates (ORR) and duration of response (DOR) among patients with various subtypes of B-cell non-Hodgkin lymphoma. Preliminary data has suggested that epcoritamab can induce responses in a significant proportion of patients, including those with heavily pre-treated disease. As a bispecific antibody, Epkinly represents a novel therapeutic approach in lymphoma, potentially providing a new treatment option for patients who have limited responses to existing therapies. Ongoing studies are necessary to further define the efficacy and safety profile of epcoritamab and to establish its place in the treatment of lymphoma.